



Ensoma
Financing Rounds
- Series A
- Series B
Round Led or Co-led By SymBiosis
Round Led or Co-led By SymBiosis
Ensoma believes the future of medicine lies within us. Its Engenious™ gene therapy platform is the first to precisely engineer any or all hematopoietic and immune cells with a one-time, off-the-shelf in vivo treatment. Engenious therapies have an unmatched capacity to deliver all modern genetic modification tools and set a new standard for versatile cell programming and control across a range of complex diseases.